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Summary
Epstein-Barr virus (EBV) adsorption to human B lymphocytes is mediated by the viral envelope
glycoprotein, gp350/220, which binds to the cell surface protein, CD21, also known as the CR2
complement receptor. Human epithelial cells also express an EBV receptor. A candidate surface
molecule of 195 kD has previously been identified on an epithelialcell line and explanted epithelial
tissue by reactivity with the CD21 specific monoclonal antibody (mAb), HB-5a. In experiments
to further characterize the epithelial cell EBV receptor, we have found that two human epithelial
cell lines, RHEK-1 and Hela, specifically bind intact EB virions. A 145-kD protein, similar
in size to B lymphocyte CD21, was specifically precipitated from surface iodinated RHEK-1
cells using the HB-5a mAb, or using purified soluble gp350/220 coupled to agarose beads. The
previously identified 195-kD protein did not bind to gp350/220 or react with two other anti-
CD21 mAbs. CD21 homologous RNA, similar in size to the B lymphocyte CD21 mRNA,
was detected in both RHEK-1 and HeLa cells. The nucleotide sequence of the epithelial cell
cDNA was identical to B lymphocyte CD21. The longest clone differs from previously reported
CD21 cDNAs in having additional 5' untranslated sequence. Polymerase chain reaction amplification
ofRHEK1- or B lymphoblastoid-derived cDNA verified that most CD21 transcripts are initiated
at least 30-50 nucleotides upstream of the previously reported mRNA cap site. These experiments
demonstrate that human epithelial cells can express CD21, and that CD21 is likely to mediate
EBV adsorption to epithelial cells.
E
BV is a human herpesvirus that causes infectious mono-
nucleosis and has been associated with a variety of human
lymphocytic and epithelial neoplasms, including Burkitt's lym-
phoma and nasopharyngeal carcinoma (for review see refer-
ence 1). Viral tropism for human B lymphocytes appears to
be due in largepart to restricted expression ofthe EBV receptor,
CD21, which also serves as the lymphocyte receptor for the
C3d,g component ofcomplement, CR2 (2-5). EBV binding
to CD21 is mediated by the viral envelope glycoprotein,
gp350/220 (6), through a peptide that is highly homolo-
gous to a portion of the C3d,g ligand (7). After binding,
virions are internalized through an endocytic mechanism that
does not appear to involve clathrin-coated pits (8).
Nascent CD21 in B lymphocytes has an apparent molec-
ular mass of 105 kD by SDS-PAGE (9), whereas the mature
glycosylated form migrates at 145 kD (5, 9) . Cloning and
sequencingof CD21 cDNA and genomic DNA from B lym-
phocytes revealed an open reading frame that encodes a pro-
tein predicted to consist of a large extracellular amino-terminal
domain comprising 15 or 16 structurally related short con-
sensus repeats (SCRs)' ; a hydrophobic transmembrane do-
main; and a short, intracellular COOH terminal tail (10-12) .
The CD21 transcript is highly spliced; each SCR domain
or contiguous pair of SCRs is encoded by an individual exon
or pair of exons (11). High resolution electron microscopy
of negatively stained, purified CD21 polypeptide has demon-
strated that the SCRs form an extended, linear structure (13) .
Recombinant molecular genetic epitope mapping has indi-
cated that CD21 specific mAbs recognize determinants in
separate SCR domains: HB-5a in SCR4 or 5; OKB-7 in
SCR1; and B2 in SCR9 to 11 (14, 15) . EBV gp350/220
binding is dependent upon partially defined structural fea-
tures of SCRs 1 and 2, and is blocked by OKB-7 binding
(14-16).
EBV infects epithelial cells as well as B lymphocytes. EBV
genomes have been detected by in situ hybridization in desqua-
1 Abbreviations used in this paper. RACE, rapid amplification of cDNA ends;
SCR, short consensus repeat.
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mononucleosispatients (17), and in salivary glandepithelium
of normal, seropositive adults (18). EBV DNA, RNA, and
proteins are invariably present in themalignant epithelial cells
of thenonkeratinizing variants of nasopharyngeal carcinoma
(19) . More recently, active replication of EBV genomes has
been demonstrated in epithelial cells of AIDS-associatedoral
hairy leukoplakia (20, 21).
Attempts to characterize the epithelial cell membrane pro-
tein responsible for EBV adsorption have yielded inconsis-
tent results. Epithelial cells express an antigen recognized by
some CD21 specific mAbs, in particular HB-5a (18, 22-26).
Arecent report describedtheidentification of a 195-200-kD
protein in epithelial cells which could be specifically precipi-
tated by HB-5a (22). However, other CD21-specific mAbs
did not react with this protein. The objective of this study
was to identify andcharacterize the EBV receptor on epithe-
lial cells. Theseexperiments were undertaken using two epi-
thelial cell lines, HeLa and RHEK-1(27) . The latter hadpre-
viously been shown to exhibit HB-5a mAb reactivity (28) .
Materials and Methods
Cell Lines.
￿
RHEK-1 (generous gift from Dr. Jong Rhim, Na-
tional Cancer Institute, Bethesda, MD) is a human keratinocyte
line that was generatedby infection of primary foreskin epithelial
cells with an adenovirus 12/SV40 hybrid virus (27). These cells
display ultrastructural features ofwell-differentiated keratinocytes
formingcytokeratin tonofilaments anddesmosomes. Though im-
mortalized, RHEK-1 cells are notfully malignant andfail to form
colonies in soft agar or tumors in nude mice. HeLa is a human
epithelial line established from aprimary cervical adenocarcinoma
(29) and has also been previously shown to express cytokeratins
(30). Molt-4 is a human T lymphocyte line that was previously
reported to express a CR2 related antigen (2, 5). 1134 is an EBV
immortalized B lymphoblastoid cell line. Raji is an EBVinfected
Burkitt tumor cell line that expresses relatively large amounts
of CD21 (6). K562 is a Philadelphia chromosome-positive hu-
man chronic myeloid leukemia cell line (6a) that does not express
CD21 (5).
Antibodies.
￿
ThemAbs used in this studyinclude: HB-5a (CD21,
IgG2a [5]), HB-5b(CD21, IgGl), HB-5c(CD21, IgGl), B2 (CD21,
IgM [31], obtained from CoulterImmunology, Hialeah, FL); OKB-
7 (CD21, IgG2b [3], obtained from Ortho Diagnostics, Raritan,
NJ); HB-12b (CD19, IgG1 [2]), 5A6(antiTAPA1, IgG1, a generous
gift from Dr. Shoshana Levy, Stanford University, Palo Alto, CA
[33]); and anti-Leu-13 (IgG1, agenerous gift from Dr. Robert Evans,
Roswell Park Memorial Institute, Buffalo, NY [34]). The HB-5b
andHB-5c antibody producing hybridomas were generatedby the
fusion of NS-1 myelomacellswith spleensof mice immunizedwith
the BJAB cell line. The HB-5b and HB-5c antibodies generated
reactivity patterns with hematopoietic cells similar to thoseof the
HB-5a antibody, immunoprecipitated a 145,000MB lymphocyte
surface molecule, andreacted with CD21 cDNA-transfected K562
cells, but not parental cells. The CD21 epitopes identified by the
HB-5b and HB-5c antibodies were different from the epitope
identified by the HB-5a antibody since the prior binding of those
antibodies did not block HB-5a antibody binding.
Indirect immunofluorescence analysis was carried out after
washing the cells twice. Suspensions ofviable cells were analyzed
for surface Ag expression by incubation for 20 min on ice with
1406 Epstein-Barr Virus Receptor on Human Epithelial Cells
theappropriate mAb as ascites fluiddiluted to the optimal concen-
trationforimmunostaining. After washing, the cells were treated
for 15 minat 4°Cwith FITC-conjugated goat anti-mouse Ig anti-
bodies (Southern Biotechnology Associates, Birmingham, AL).
Single-color immunofluorescence analysis wasperformedon a flow
cytometer (Epics Profile; Coulter Electronics, Hialeah, FL). 10^
cells were analyzed in each instance and all histograms are shown
on a three decade log scale. For immunofluorescent visualization
ofmembrane CR2, live cells were incubatedin chamberslides with
the CR2-specific mAbs HB-5a, OKB-7, and B2.
VirusBinding.
￿
RHEK-1 andHeLa cellswere grownovernight
in 8-well chamber slides (Nunc, Inc., Naperville, IL) at an initial
density of 105 cells/ml. Raji cells were grown in suspension to a
density of 106 cells/ml. Cells were washed with PBS plus 10%
goat serum, and incubated with B95-8 virus (virus titer: 108 trans-
forming units/ml) for 1 h on ice. After washing with PBS, cells
were incubatedfor 1 h on icewith 2L10 mAb, specific for theEBV
envelope glycoprotein gp350/220(gift of Dr. G. Pearson, George-
town University, Wash. DC). FITC-conjugated goat anti-mouse
antibody was added. Cells were visualized under epifluorescence
with a Zeiss Axiomat photomicroscope (Thornwood, NY).
RNA Analysis.
￿
Total cellular RNA was purified by acid gua-
nidinium phenol chloroform extraction (35). The polyadenylylated
RNA fraction wasisolated by oligodeoxythymidine cellulosechro-
matography. RNA samples (IB4, 4 fig/lane; allother samples, 10
,ug/lane) were size fractionated in 0.66 M formaldehyde, 0.8%
agarose, blotted onto activated nylon membrane, and hybridized
with a NP-labeled, CD21 specific probe. The probe was generated
using apreviously described cDNA clone isolated from theBlym-
phocyte cell line Raji (36) and consists of the 1.76- and 1.45-kb
EcoRl fragments that comprise the open reading frame. After
washing under conditions of moderate stringency (25°C below
melting temperature), the filter was exposed to preflashed film
(Kodak XAR; Eastman Kodak Co., Rochester, NY) for 7 d. Rela-
tive RNAabundancelevels were determined by direct densitometric
scanning of autoradiographs usingaspectrophotometer (model DU-
8; Beckman Instruments, Inc., Fullerton, CA) equipped with a
slab gel Compuset module (Beckman Instruments, Inc.), and cor-
rected for the total amounts of RNA loaded in each lane.
cDNA Library Preparation.
￿
5 Fig of polyadenylylated RHEK-1
RNAwas reversetranscribed usingMoloney murine leukemia virus
reverse transcriptase (Super Script; Bethesda Research Laboratories,
Gaithersburg, MD). Second-strand synthesis wasperformedusing
Escherichia coli DNApolymerase Iandribonuclease H. Aftermeth-
ylation, linker ligation, andEcoRl restriction digestion, thecDNA
was size selected by Sepharose 4B gel filtration chromatography,
and cloned into Xgt10. ti2 x 106 recombinant phage were
screened by in situ plaque hybridization using "P-labeled CD21
specific probe. Positive clones were plaque purified andcDNA in-
serts were subdoned into pBluescript (Stratagene Inc., La Jolla,
CA) for sequence analysis.
PCR Amplification.
￿
The "rapid amplification of cDNA ends"
(RACE) procedureof Frohman et al. (37) was used to characterize
the5' ends of CD21 transcripts. First-strand cDNA synthesiswas
performed on 2.5 jig ofpolyadenylylated RNA from RHEK-1 or
IB4 cells, using the oligonucleotide primer, CR2-8 (ATGTC-
CATTGTGGATCATA)complementary to a region in thethirdexon
of the CR2 mRNA. The cDNA products were polydeoxyadeny-
late tailed using terminal deoxynucleotidyl transferase and dATP.
Products of a mock reverse transcription reaction, in which Hz0
wasaddedin placeofRNA, were used in negative control amplifica-
tions. Initial amplification was carried out using the following
oligonucleotide primers at the concentrations indicated: 0.2 EiMT adaptor (GCCTCGAGCTCTAGAATTCCTTCTI,) ; 1.0 JIM
adaptor (GCCTCGAGCTCTAGAATTCCT); and 1.0pM CR2-10
(ACACAGGTTGGTAGTCGT) . The CR2-10 primer matches a
sequence in the second exon of the CR2 transcript . The ampli-
fication reactions were performed sequentially as follows : 94° 1 min,
48° 3 min, 72° 5 min (2 cycles) ; 94° 1 min, 50° 3 min, 72° 5
min (2 cycles); 94° 40 s, 53° 1 min, and 72° 3 min (35 cycles) .
5 pl of the products of the first amplification were subjected to
a second round of amplification using 1.0 pM Ad and 1.0 pM
CR2-14 (ATTGAAGAATTCACATTTAGGAGCAGGTTTA) oli-
gonucleotide primers . TheCR2-14 primer is specific forasequence
in the second exon of the CR2 mRNA, upstream of primer
CR2-10 . Twonucleotide mismatches were incorporated in CR2-14
to generate an EcoRl restriction site to facilitate subcloning and
analysis of amplification products . Amplification reaction condi-
tions were 94° 1 min, 55° 2 min, and 72° 3 min (40 cycles) . 15
pl of the second amplification reaction products were size fraction-
ated in 1.2% agarose and transferred to charged nylon membrane
(GeneScreen Plus ; NewEngland Nuclear, Billerica, MA) . The filter
was hybridized sequentially with the following "P-end-labeled oli-
gonucleotide probes (see Fig. 3) : CR2-11 (GCCCGCCTCTC-
CTGGCTCAC) ; CR2-12(CTAGCACGTGTGCCGGACAC) ; and
CR2-15 (TGCTTGCTGCTCCAGCCTTGC) . CR2-11 and -12
correspond to sequences upstream of the transcriptional initiation
site previously identified in Raji cells (12, 38) . CR2-15 matches
the sequence at the 5' end of the Raji CR2 transcript (38) . Filters
were washed at 60°C in 0.5x SSC (20xSSC : 3.0M NaCl, 0.3
MNaCitrate), 1% SIDS, andexposed 4-12hto KodakXARfilm .
Theremainder oftheIB4cDNA amplification products were EcoRI
digested, subcloned into pBluescript, and sequenced .
Protein Labeling.
￿
Confluent cultures of 2-3 x 108 RHEK-1 ep-
ithelial cells were removed from plates by scraping in ice-cold PBS/1
mMEDTA, pelleted, andwashed once withPBS. Suspension cul-
tures of Raji cells (107) were pelleted directly and washed once in
PBS . After resuspending in PBS, cells were incubated 15 min at
4°C with the water-soluble Bolton-Hunter reagent, sulfosuccini-
midyl-3-(4-hydroxyphenyl)propionate (sulfo-SHPP, Pierce Chem-
ical Co ., Rockford, IL) at 0.2 mg/ml . Cells were washed twice,
suspended in PBS, and radioactively labeled using lactoperoxidase
and ...1 (1 .0 mCi/ml) . For metabolic labeling studies, RHEK-1,
HeLa, and IB4 cells were grown to 106 cell/ml. Labeling was car-
ried out overnight by addition of 1 mCi [3sS]methionine (New En-
gland Nuclear) to 108 cells in methionine-free DMEM medium
supplemented with 10% dialyzed fetal bovine serum .
Purification ofSolublegp350/220 .
￿
Gp350/220 was purified by
the previously describedion-exchange chromatography procedure
(39) from the supernatants ofGH3-019 cells grown in DMEM
supplemented with 5% FCS . These cells constitutively secrete a
soluble form ofgp350/220 lacking the transmembrane domain of
the viral envelope protein (40) . Cell supernatants were adjusted to
20 mM piperazine, pH 5.4, 0.5% NP-40, 0.1 M betaine (buffer
A) . The supernatant was runthrough aMonoQXK 16/20 prepara-
tive column (Pharmacia/LKB, Piscataway, NJ), at a flow rate of
2 ml/min . The column was washed with buffer A at a flow rate
of 1.25 of ml/min, and eluted by 150ml 0-0.5MNaCl linear gra-
dient . Fractions were assayed by Western blot using 2L10 primary
antibody. Samples containing gp350/220were pooled, diluted 1.5-
fold in buffer A, and applied to a second MonoQHR 5/5 analyt-
ical column at a flow rate of 1.0 ml/min . The column waswashed
with buffer A and eluted with 30 ml 0-0.5 M NaCl linear gra-
dient . Fractions containing gp350/220 were collectedandincubated
withJacalin-agarose (Sigma ChemicalCo., St . Louis, MO) for4 h
at4°C . The agarose beadswere washed with PBS, then eluted with
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0.1Mmethyl-a-galactopyranoside in PBS. The eluate was dialyzed
against PBS andconcentrated by centrifugation on Centricon-100
filters (Amicon Corp., Beverly, MA) . Total protein yield was de-
termined by the Bradford Coomassie stain assay (Bio-Rad Labora-
tories, Richmond, CA). -8 pg of the final purification product
was analyzed by SDS-PAGE . Proteins were visualized by silver
staining (Bio-Rad Laboratories) .
Coupling ofReagents to Affi-Gel .
￿
Antibody HB-5c (0.5 mg/ml)
was coupled to agarose beads (Affi-Gel 10, Bio-Rad Laboratories);
BSA (0.5 mg/ml) and gp350/220 (0.3 mg/ml) were coupled to
Affi-Gel 15 agarose beads . The coupling was done by incubating
the protein solution with beads for4h at 4°C . The unreacted coup-
ling sites were blocked by 0.2M glycine . Thecoupled agarose beads
were washed with PBS and stored at 4°C .
Immunoprecipitation ofCR2 .
￿
Labeled cells were lysed in buffer
(108 cell/2 ml lysis buffer) containing 120mM NaCl, 10 mM Tris
(pH 7.5), 1% NP-40, 2 14g/ml aprotinin, 1mM PMSF. Insoluble
material was removedby centrifugation . The lysates were precleared
with agarose beads coupled with BSA for 2 h at 4°C, and were
divided into replicate samples . Agarose beads coupledwith theCR2-
specific mAbs HB-5a (5), HB-5b, HB-5c, purified soluble gp350/
220, or BSA were added to each sample, respectively. The lysates
were incubated with beads overnight . The immunoprecipitated
sampleswere run on 7.0% SDS-PAGE and visualized by autoradi-
ography .
Results
As expected from previous studies ofhuman epithelial tissues
and cell lines, theHB-5a antibody recognized an antigenon
the plasma membranes of live RHEK-1 and HeLa cells in
indirect immunofluorescence assays (data not shown) . In con-
trast, two other CD21 specificmAbs, OKB-7 andB2, yielded
only weak or equivocal membrane fluorescence (data not
shown), which is consistent with previous studies of epithe-
lial cells . All three antibodies reacted with the_plasma mem-
branes of live Raji cells, an EBVpositive Burkitt lymphoma
cell line, though reactivity with OKB-7 was consistently
weaker than withB2 or HB-5a (datanotshown) . These results
confirm theprevious inconsistency in the reactivity ofCD21-
specific mAbs with an epithelial cell surface antigen (18,
22-26) .
Virus Binding.
￿
RHEK-1 and HeLa epithelial cells bound
intact EB virions, albeit to a lesser extent than B lympho-
cytes . Concentrated preparations ofB95-8 virus were incubated
with subconfluent RHEK1 or HeLa cells cultured in chamber
slides . After extensive washing, immunofluorescence staining
was performed using themAb 2L10, specific for EBV enve-
lope glycoprotein, gp350/220 . Although this glycoprotein
has previously been shown to mediateEBV binding to CR2,
the epitope recognized by 2L10 is distinct from the CR2
binding domain (6, 7) . Focal, punctate fluorescence repre-
senting viral particleswas observed alongcytoplasmicmem-
brane margins in both RHEK-1 and HeLa cells (Fig. 1 c,
e, and g) . The majority of RHEK-1 cells bound variable
numbers of virions, ranging from one to several virions per
cell . Theselected fields depicted show somewhat higher levels
than were generally observed. RHEK-1 cell virus binding
levels were typically5- to 10-foldlowerthan in 1134, aBlym-
phoblastoid cell line establishedbyEBV infection of primaryB lymphocytes in vitro (Fig. 1 a) . The substantially greater
binding to nonadherent IB4 cells is not reflected in pho-
tomicrographs because these were restricted to a single focal
plane (Fig. 1 a) . HeLa cells on average bound significantly
less virus than RHEK-1 . InHeU cultures, virusbound pre-
dominantly to the surfaces of rounded cells, in contrast to
the more common flattened or spindle-shaped cells which
did not bind virus detectably (Fig. 1, g and h) . K562, a chronic
myeloid leukemia-derived cell line that does not express CD21
was used as a negative control for virus binding. No fluores-
cence was observed with the negative control line K562 after
incubation with virus and 2L10 antibody, or with epithelial
cells that had not been incubated with virus (data not shown) .
RNA Analysis.
￿
The RHEK-1 and HeLa cell reactivity
with HB-5a mAb and virus binding properties are compat-
ible with the hypothesis that the EBV receptor protein is en-
coded by aCD21-homologousmRNA . The absence of sig-
nificant reactivity with B2 and OKB-7 would necessitate a
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Figure 1 . Immunofluorescence detection of
Epstein-Barrvirion binding to epithelial cells. Con-
centrated EB virus stocks (108 transforming
U/ml) were incubated for 1 h with epithelial cell
cultures in chamber slides. Cells were washed and
stained with the mAb, 2L10, specific for the viral
envelope glycoprotein, gp350/220 . As a positive
control, IB4 lymphocytes in suspension culture
were similarly stained inmicrotiter wells and visual-
ized. Bound EB virions are visualized as punctate
fluorescent structures on the cell surfaces (white
arrows ; a, c, e, andg) . Corresponding cell surfaces
are indicated by white arrows in phase contrast
images (b, d, f, and h) at the right of each im-
munofluorescence photomicrograph . Numerous
virions are bound diffusely to the surfaces of IB4
B lymphoblastoid cells (a) . Significantly fewer
bound virions are observed along the cytoplasmic
margins of RHEK-1 (c and e) and HeLa epithelial
cells (g) . a-f,
￿
x1000 ; g and h,
￿
x450.
more complicated model such as preservation of some but
not allCD21 epitopes because ofdifferential splicing. To pursue
this hypothesis, RNA was extracted, size fractionated on a
formaldehyde agarose gel, and hybridized with a CD21-specific
probe at moderate stringency. A 4.3-kbRNA was detected
in RHEK-1 cell RNA (Fig. 2), matching in size the more
abundant, predominant CD21 RNAs of the B lymphocyte
line, 1134 and the T cell line, Molt-4 . An RNA species of
identical size was detected at low levels in RNA extracted
from HeLa cells . Anumber of less abundant CD21 homolo-
gous RNAs, both larger and smaller than the predominant
4.3-kb message, are evident in 1114, as have been observed
in other B lymphocyte RNA preparations (11) . None of these
latter RNAs were detected in epithelial cellRNA prepara-
tions. A 0.55-kb RNA, however, was evident in HeLa and
MOLT -4 RNA . In IB4 cells, the 4.3-kb RNA is N50-fold
more abundant than in RHEK-1 cells, and 90-fold more abun-
dant than in HeLa cells as assessed by densitometric scanningFigure 2 .
￿
CR2 RNA expression in epithelial cell lines. RNA was iso-
lated from the following cell lines: MOLT-4 (humanT acute lymphoblastic
leukemia cell line) ; IB4 (human B lymphoblastoid cell line) ;CV-1 (simian
fibroblast) ; RHEK-1, and HeLa (human epithelial cell lines) . 4 (IB4), or
10 ug (all other cell lines) polyadenylylated RNA was size fractionated,
blotted, and hybridized to a 32P-labeled CR2 probe. A 4.3-kb band, in-
dicated by the arrow, is detected in MOLT 4, IB4, RHEK-1, and HeLa
cells . Positions ofribosomalRNAbands are indicatedby dashes (18S, 28S) .
A 0.55-kbRNA species ofunknown structure is detected in MOLT-4 and
HeLa RNA .
A
B
5'
￿
E
￿
E
￿
3.
AAAAA
ATG
0.40
4A
4s,26
, 50
-53
￿
-11
￿
+1
CGCTCAGAACTAGCACGTGTGCCGGACACTATTTAAGGGCCCGCCTCTCCTGGCTCAC~TGCTTGCTGCTCCAGCCTTGCCC
cat-12
￿
Cat-11
￿
Cat-15
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of autoradiographs, normalized for total RNA loaded per
lane . Thus the abundance of the CD21 homologous RNA
in the epithelial cells correlates qualitatively with relative virus
binding activity : IB4 > RHEK-1 > Hela.
To identifyCD21 homologousRNA in human epithelial
tissues,RNA was extracted from uterine cervical epithelium
dissected from freshly excised surgical specimens and analyzed
byRNA blot hybridization . A 4.3-kbRNA was specifically
detected in this preparation with CD21 probe (data not
shown) . However, rehybridization of this blot with Igrc L
chain probe readily detected significant quantities of ismRNA.
Thus, the epithelial tissue preparation was likely contami-
nated with lymphocytes or plasma cells .
The RHEK-1 RNA homologous to CD21 was cloned and
sequenced to determine its precise relationship to theB lym-
phocyte message. A RHEK-1RNAcDNA library was con-
structed and screened using a CD21 probe. Four indepen-
dent cDNA clones were isolated from an initial screening
of 2 x 106 recombinant bacteriophage. The structure of
each clone was determined by restriction mapping and se-
quence analysis (Fig. 3 A) . All four clones lacked the variable
exon of theB lymphocyte CD21mRNA (41), encoding the
SCR domain designated either 10b (11) or 11(13) . Complete
sequencing of the largest clone, RH50, indicated precise
nucleotide identity with a previously publishedCD21 cDNA
(11-13), though the untranslated leader sequence of the epi-
thelial cDNA was longer than had been previously described
for B lymphocyte CD21 (12, 38) . The longer leader placed
the transcriptional initiation site at least 11 (38) or 32 (12)
nucleotides upstream of previously mapped B lymphocyte
CD21 mRNA cap sites (Fig . 3 B) .
Figure 3 .
￿
Structure ofepithelial cell CR2mRNA
andcDNA clones . (A) Structure oftheCR2 message
is shown schematically at the top, indicating positions
of the initiation codon (A7G), two EcoRI restriction
sites (E), and polyadenylate tail (AAAAA) . (Filled box)
CR2 open reading frame. Structures of four indepen-
dent CR2 cDNA clones (4A, 4B, 26, and 50) from
the epithelial cell line RHEK-1 are shown below.
(Hatched box at the 5' end of clone 50) Additional un-
translated sequence upstream ofthe transcriptional ini-
tiation site previously identified in Raji B lymphocytes
(32) . (B) The highlighted nucleotide at position +1
(rightward arrow) represents the previously mapped Raji
initiation site (32) . The first nucleotides of RHEK-1
cDNA clone 50, and of the longest clone obtained
by PCR amplification of IB4 cDNA, are highlighted
at positions -11 and -53, respectively. (Underlined
bases) Sequences of oligonucleotide probes CR2-11,
CR2-12, and CR2-15 . (C) Products of PCR am-
plification of polydeoxyadenylate tailed cDNA from
IB4 and RHEK-1 cells were hybridized with 32p-
labeled oligonucleotide probes CR2-11, -12, and -15 .
The positions ofDNA markers are shown (left) with
sizes in base pairs indicated . All three probes detect
prominent bands at -430 nucleotides inbothRHEK 1
and IB4 amplification products. Shorter exposure in-
dicates the presence of a discrete minor band at -380
nucleotides in RHEK-1 amplification products hybrid-
ized with the CR2-15 probe. Nobands are detectable
in control reaction products (CON) .The use of this novel CD21 transcriptional initiation site
was further analyzed using the RACE technique (37) to
amplify the 5' ends of the 1134 B lymphocyte and RHEK-1
epithelial RNAs. RHEK-1 and IB4 first-strand cDNA prepa-
rations were made using an oligonucleotide primer com-
plementary to a sequence encoding the thirdSCR . ThecDNA
was polydeoxyadenylate tailed and amplified sequentially using
a 5' poly-dA specific adapter primer, and nested 3' primers
specific for sequences in the second exon of theCR2mRNA .
This technique should amplify the beginning of all CR2 tran-
scripts. A control amplification was performed in parallel on
the products of a mock reverse transcription reaction to which
H2O was added in place of RNA. The products of the
second amplification were blotted and hybridized with 32p-
end-labeled oligonucleotide probes from the 5' untranslated
sequence (CR2-15) and putative promoter region (CR2-11,
12) of the CR2 transcript (Fig. 3 C) . Amplification primers
were selected to span one splicejunction . As the size of the
intervening intron exceeds 10 kb (11, 38), detection of amplified
genomicDNA or unprocessed primary transcript is not pos-
sible . Specific products were routinely detectable after initial
amplification of 1134 B lymphocytecDNA . Specific products
from RHEK-1 cDNA, however, were not detectable at this
stage, necessitating the second amplification step. All three
probes detected diffuse bands of similar size (-430 bp) in
both 1134 and RHEK-1 amplification products . Short exposure
autoradiographs indicate that the apparent slight discrepancy
in size between IB4 and RHEK-1 products detected with
the CR2-12 probe is due to trailing off ofhigher and lower
molecular weight products above and below predominant
bands ofidentical size in each lane . This artefact was not ob-
served in multiple other hybridizations (data not shown) .
Given the size ofthe poly-dA adapter primer (40 nucleotides),
these products map the transcriptional initiation site at or
near 50 nucleotides upstream of the previously published
mRNA cap site. Smaller products corresponding to transcripts
initiated at either of the previously identified Raji cap sites
(12, 38) were not evident in amplification products from 1134
B lymphocyte RNA . A minor band of-380 by was, how-
ever, detected after prolonged exposure ofCR2-15 probe hy-
bridized RHEK-1 amplification products (Fig . 3 C) . Se-
quencing of three pBluescript clones of 1134 PCR products
indicated heterogeneity in the start sites within a 25-bp re-
gion, the longest clone initiating at position -53 (Fig . 3
B) . Amplification ofHeLa cDNA with the CR2-12 and -14
oligonucleotide primers confirmed transcriptional initiation
from this region in these cells as well (data not shown) .
CD21 Immunoprecipitation.
￿
The preferential reactivity of
epithelial cells with the H13-5a mAb versus B2 and OKB-7
in the face of an identity toB lymphocyte CD21 at the RNA
level could be due to crossreactivity of HB-5a with another
epithelial cell surface protein, to a difference in posttransla-
tional processing ofCD21 in epithelial cells or to partial oc-
clusion of the B-2 and OKB-7 epitopes because of another
epithelial cell surface protein . A 195-kD epithelial cell sur-
face protein had previously been described to react withHB-
5a . To investigate further the basis for the HB-5a reactivity
and the relationship of the 195-kD protein to CD21, im-
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munoprecipitations were performed using HB-5a and two
other CD21-specific mAbs, HB-5b andHB-5c. As expected,
all three reagents precipitated a 145-kD protein from
135S]methionine-labeled extracts of the B lymphocyte line,
1134 (Fig. 4 A) . The HB-5c-coupled beads were somewhat
variable in their reactivity and slightly less efficient than HB-
5a, whereas the HB-5b reagent was considerably less active
(Fig. 4 A) . A single 195-kD protein was clearly identified
in HB-5a immunoprecipitations from bothRHEK1 and HeLa
cells (Fig . 4, A and B) . The HB-5b and HB-5c antibodies,
however, consistently failed to precipitate this protein from
RHEK-1 cells. Since HB-5c reactivity with 1134 CD21 was
almost as strong as HB-5a, the failure to precipitate the 195-
kD protein with HB-5c is confirmative of the previous ob-
servation that the 195-kD protein lacks other CD21 epitopes .
To increase the sensitivity of these assays RHEK-1 cells
were surface labeled with ' 25 1, lysed in nonionic detergent,
and the HB-5a reactive proteins were identified . Proteins of
195 and 145 kD were specifically precipitated from RHEK-1
cell lysates by the HB-5a mAb (Fig. 5 A) . The less promi-
nent 145-kD protein was identical in size to CD21 precipi-
tated with HB-5a from surface-labeled Raji cells and run as
a control in parallel (data not shown) .
To ascertain which of these proteins is a receptor for the
EBV gp350/2201igand, 1251 surface-labeled RHEK-1 cell ly-
sates were reacted with gp350/220 bound to an inert ma-
trix. Recombinant gp350/220 consisting of the entire ex-
ternal domain is an efficient CD21 ligand (40) . This reagent
specifically precipitated a 145-kD protein from 1251 labeled
RHEK-1 cells, and a protein of identical size from Raji B
lymphocytes processed in parallel (Fig . 5 B) . It is significant
that in this and multiple other experiments, the 195-kD pro-
tein was not precipitated by gp350/220 (Fig . 5 B) . However,
the 195-kD protein was readily recovered from the superna-
tants of the gp350/220 precipitation after specific removal
of gp350/220 bound material (Fig . 5 C, lane HB5a) . In con-
trast, HB-5a precipitation of this supernatant no longer de-
tected the 145-kD protein, indicating that it had been quan-
Figure 4 .
￿
Immunoprecipitation of theMAD protein. IB4, RHEK-1
(A), and HeLa cells (B) were metabolically labeled with [35S]methionine
overnight . Lysates from 10' cells were precipitated with three CR2-specific
mAbs, HB-5a (5a), HB-5b (5b), HB-5c (5c), and the control antibody
Upc10 (upc10). All three CR2 antibodies precipitate the 145-kD CR2protein
from IB4 B lymphocytes (A, large arrow) . A 195-kD protein (small arrow)
is precipitated only by HB-5a from both RHEK-1 (A) and HeLa cell ly-
sates (B) .Figure 5 .
￿
Immunoprecipitation of epithelial CR2 . Raji and RHEK-1
cells were 1251-surface labeled. Direct precipitation of RHEK-1 lysates with
HB-5a specifically detects both the 195-kD (smallarrow) and 145-kD (large
arrow) proteins (A) . Cell lysates from 2 x 106 Raji cells or 9 x 107
RHEK-1 cells were precipitated with purified soluble gp350/220 (gp350)
or BSA coupled to agarose beads (B) . A band at 145 kD (large arrow) is
evident in both Raji and RHEK-1 gp350/220 precipitates, but is absent
from BSA precipitates of RHEK-1 lysates. The 195-kD protein precipitable
with HB-5a is not detected in the gp350/220 precipitation . (A diagonal
split in the gel arose during drying but is located above the expected posi-
tion of the 195AD protein and did not involve any loss of gel material .)
The RHEK-1 cell supernatant after gp350/220 precipitation (RHEK-1
gp350 Sup) was reprecipitated with two CR2-specific mAbs, HB-5a (HB5a)
and HB-5c (HBSc), and with BSA control beads (C) . The 145AD CR2
protein is not detectable in this supernatant . A 195AD protein (small arrow)
is specifically precipitated from the supernatant by HB-5abut not by HB-5c.
titatively removed from the epithelial cell lysate by the
gp350/220 coupled beads (Fig. 5 C, lane H135a) . These ex-
periments demonstrate that RHEK-1 cells have on their sur-
face a small amount of a 145-kD protein indistinguishable
from CD21, and that the 195-kD protein does not interact
with gp350/220 .
Immunoprecipitation of 35S-or 1151-labeled HeLa extracts
with HB-5a antibody consistently detected the 195-kD pro-
tein but failed to identify the 145-kD species (Fig. 4 B and
data not shown) . This finding was not unexpected given the
small amount of the 145-kD protein detected in RHEK-1
cells, and the significantly lower abundance of theCD21 RNA
in these cells as compared with RHEK-1 .
Expression ofCD19, TAPA-1, andLeu-13 by Cell Lines.
￿
The
CD21 protein forms a complex with multiple cell surface
molecules on lymphocytes (42) including CD19 (43), TAPA-1
(33), and the Leu-13 antigen (44) . Since this multimolecular
complex may be significant in CD21 function, the distribu-
tion ofeach protein on cell lines used in this study was exam-
ined by flow cytometry after reaction with specific antibodies
(Fig. 6) . As has been previously found on B lymphoblastoid
cell lines, no strict correlation between the patterns of ex-
pression of these four antigens was found . CD21, CD19,
TAPA-1, and Leu-13 were expressed by the 1134 B cell line,
TAPA1 and Leu-13 were expressed byRHEK cells, andTAPA1
was expressed by HeLa cells . These results are consistent with
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Figure 6 .
￿
Expression of CD19, TAPA-1, and Leu-13 by epithelial cell
lines . Cell surface antigen expression was determined by indirect im-
munofluorescence staining with flow cytometry analysis. Background
staining obtained with unreactive mouse Ig as a control is shown as a
filled histogram (top) . Staining results obtained with the indicated anti-
bodies, CD19 (HB13b), TAPA-1 (5A6), and Leu-13 are shown as open
histograms. Fluorescence intensity is shown on a three decade log scale.
the prior observation that CD19 andCD21 can independently
associate with TAPA-1, which independently associates with
the Leu-13 protein (42) .
Discussion
These experiments demonstrate that the human keratino-
cyte cell line, RHEK-1, expresses low levels ofCD21 RNA ;
that the low RNA level correlates with alow level of expres-
sion of a protein similar in size and HB-5a reactivity to B
lymphocyte CD21 ; that the 145-kD protein binds to the EBV
ligand, gp350/220 ; and, that thelow level CD21 expression
correlates with a low level of EBV receptor activity. Thus,
CD21 is almost certain to be the EBV receptor on RHEK-1
cells . A previously described 195-kD protein (22) was pre-
cipitable with HB-5a, but failed to bind gp350/220 or to
react with the other anti-CD21 antibodies, HB-5b and HB-5c .
The similar size of the CD21 glycoprotein in epithelial
cells and B lymphocytes is expected given the RNA sequence
identity and the consistent size ofCD21 glycoprotein previ-
ously noted in a variety of cell types, including murine L
cell fibroblasts (45), Rat-1 fibroblasts (X . Tong, unpublished
observations), SVK and SCC human keratinocytes (36), and
the human myeloid leukemia cell line K562 (F. Wang, un-
published observations) after transfection with B lympho-
cyte CD21 cDNA under control of a heterologous promoter.
These results suggest similar patterns ofposttranslational pro-
cessing of CD21 polypeptide in diverse tissues . Moreover,
expression ofthe B lymphocyte CD21 cDNA in SVK orSCC
keratinocytes renders these cells susceptible to EBV infection
in vitro (36), confirming that this glycoprotein can serve as
a functional viral receptor in epithelial cells .
It is likely that the CD21 expression in the RHEK-1 cell
line represents a normal feature of epithelial cells rather than
a consequence of idiosyncratic or global transcriptional acti-
vation in a transformed cell line. First, RHEK-1 cells exhibit
a remarkably well-differentiated phenotype in vitro, syn-
thesizing the epithelial marker protein, keratin, and formingultrastructural elements characteristic of keratinocytes, in-
cluding tonofilaments and desmosomes (27) . These cells are
not fully transformed as evidenced by their failure to form
tumors in nude mice or colonies in soft agar. Second, the
CD21 RNA is expressed in an independent epithelial cell line,
HeLa, which also synthesizes cytokeratins, but displays pheno-
typic features and growth characteristics distinct from those
ofRHEK-1 . Third, RHEK-1 cellsdo not inappropriately ex-
press other markers ofB lymphocyte differentiation, such as
rc L chain transcripts (data not shown) . Together these findings
suggest that the low level CD21 expression in these cultured
epithelial cells in vitro reflects a biologically relevant process
likely to constitute a feature of some epithelial cells in vivo .
CD21 RNA has been previously detected in the nasopharyn-
geal carcinoma cell lines C15 and C18 using a ribonuclease
protection assay (46) providing an important precedent for
these studies . However, the size or sequence of the CD21
RNAs in these cell lines was not determined, nor was pro-
tein expression examined . Further, these nasopharyngeal car-
cinoma cell lines are EBV infected . Previous studies have
demonstrated that EBV can induce CD21 expression in B
lymphocytes (46, 47) .
A second important precedent was the demonstration of
EBV receptors on epithelial cells by ultrastructural studies
ofvirus binding to primary explant cultures ofnormal human
uterine exocervix (48) . Attempts to identify and characterize
this receptor by immunological techniques, however, have
led to conflicting results . Immunostaining studies using the
HB-5a mAb have consistently demonstrated strong plasma
membrane reactivity in epithelial cells of nasopharynx, tongue,
tonsil, and uterine exocervix, as well as in some cultured epi-
thelial cell lines (22-24, 26) . Reactivity of tissues was gener-
ally described as confined to suprabasal spinous layers (18,
22, 23) . Similar studies using the B2 antibody have revealed,
in some cases, prominent membrane and cytoplasmic staining
of epithelial cells (18, 22, 26) . Other studies have failed to
detect B2 reactivity (25), although the B2 epitope may have
been sensitive to conditions of tissue fixation even if it had
been present in sufficient abundance (26) . Typically, all other
CD21 antibodies, including OKB-7, failed to detect any epi-
thelial cell antigens (24-26) .
The seemingly conflicting results of these earlier studies
may be accounted for in part by the data reported here. CD21
expression in RHEK-1 and HeLa cells was consistently low,
and the glycoprotein was barely detectable with specific anti-
body or with the EBV ligand gp350/220 . In RHEK-1 cells,
which contained more CD21 mRNA than HeLa, demon-
stration of the 145-kD protein required high specific activity
lysates from large numbers (108) of cells. Not surprisingly,
repeated attempts to identify this protein in HeLa cells were
unsuccessful because of substantially lower expression levels .
In light of the low abundance of the CD21 protein in our
studies, it is likely that the membrane staining observed using
the HB-5amAb is largely or entirely a consequence ofdetec-
tion of the previously described 195-kD protein . The ability
ofHB-5a to recognize this protein has been documented by
us (Figs . 4, A andB ; and 5,A and C) and others (22) through
immunoprecipitation studies . Labeling by surface iodination
1412
￿
Epstein-Barr Virus Receptor
confirms its association with the cell membrane. Neverthe-
less, this protein has no detectable gp350/220 binding ac-
tivity and is unlikely to be an EBV receptor. It should be
noted that HB-5a reactivity alone does not necessarily imply
EBV binding properties since theEBV binding site and HB-5a
epitope reside within physically separated CD21 SCRs (14-16) .
CD21 is part of a multimolecular complex on the surface
ofB lymphocytes that includes CD19, TAPA-1, and Leu-13
(42, 43) . In addition to biochemical evidence that CD19,
CD21, TAPA-1, and Leu-13 form a multimolecular complex,
cocapping and functional studies demonstrate that they nor-
mally associate on the cell surface (43) . These observations
are consistent with the possibility that CD19, CD21, TAPA-1,
and Leu-13 assemble into a cell surface complex that may be
involved in the generation of transmembrane signals related
to receptor internalization . Since CD21 has the capacity to
interact directly with the TAPA-1/Leu-13 complex, their pres-
ence on RHEK-1 cells is consistent with the possibility that
CD21 and TAPA-1 may significantly associate on some epi-
thelial cells .
These experiments also demonstrate that CD21 transcripts
in both epithelial cells and B lymphocytes are initiated largely
or predominantly from multiple sites located considerably
upstream from previously identified initiation sites (12, 38) .
Observations in support of this conclusion include the
identification of an epithelialcDNA clone initiating upstream
of the previously mapped mRNA cap sites (Fig. 3, A and
B) ; analysis by oligonucleotide hybridization and sequencing
of 5' RACE PCR amplification products generated from both
epithelial and B lymphocyte cDNA (Fig . 3 C) ; and conven-
tional PCR amplification ofCD21 cDNA using oligonucle-
otide primers from the purported promoter region (data not
shown) . Heterogeneity among cloned IB4 PCR products and
the diffuse nature of the PCR bands detected by hybridiza-
tion suggest that multiple initiation sites may be utilized in
CD21 gene transcription . Noteworthy in this regard is the
lack of canonicalCAAT andTATA box structures in theCD21
promoter. Absence of these structures is typically associated
with heterogeneity in transcriptional initiation sites (49) . An
analogous situation exists in the promoter ofthe CD20 (B1)
gene, which also lacks a canonical TATA box and initiates
transcription from multiple sites (50) . Initiation from up-
stream sites in the CD21 promoter may be related to GC-
rich sequences, including AP-2 and SP1 elements present in
this region (38) . The sequence TATTT, located 30 nucleo-
tides upstream of one previously mapped initiation site, has
been proposed as a functional TATA box variant (38) . Aweak
band detected by the CR-15 probe in amplified RHEK-1
cDNA (Fig. 3 C) may reflect low level utilization of the ini-
tiation site under the control of this element .
Initiation from an upstream site could affect CD21 poly-
peptide structure. The additional 5' nucleotide sequence, which
lacks a stop codon in frame with the CD21 reading frame,
could potentially be translated to generate a novel protein
distinguished from CD21 by additional amino terminal se-
quence . Absence of an in-frame initiator methionine codon
anywhere in this region (38), however, makes this possibility
unlikely.
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